Stock MBRX MOLECULIN BIOTECH, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Analyst Reco. Moleculin Biotech, Inc.

Equities

MBRX

US60855D3098

Delayed Nasdaq
Other stock markets
 02:27:14 2024-05-09 pm EDT 		5-day change 1st Jan Change
4.965 USD +5.64% Intraday chart for Moleculin Biotech, Inc. -3.59% -61.44%
May. 07 Transcript : Moleculin Biotech, Inc. - Special Call
May. 07 Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data CI

Analyst Reco.

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Maxim Adjusts Price Target on Moleculin Biotech to $20 From $45, Maintains Buy Rating
MT
HC Wainwright Initiates Moleculin Biotech With Buy Rating, Price Target is $3
MT
Moleculin Biotech, Inc. Announces Positive Interim Data in Annamycin Clinical Trials: MB-106 AML Trial Complete Response (CR) Rate of 38% and MB-107 STS Lung Mets Trial Median Phase 1B Extended Overall Survival of 11 Months
CI
Roth Capital Adjusts Moleculin Biotech's Price Target to $16 From $29, Reiterates Buy Rating
MT
MOLECULIN BIOTECH : Oppenheimer Adjusts Moleculin Biotech's Price Target to $18 From Post-Split Adjusted $12, Keeps Outperform Rating
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MBRX Stock
  4. News Moleculin Biotech, Inc.
  5. Analyst Reco.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW